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ABSTRACT: A versatile method for the synthesis of 
enantioenriched N-H sulfoximines is reported. The approach 
stems from the organomagnesium-mediated ring opening of 
novel cyclic sulfonimidate templates. The reactions proceed in 
high yield and with excellent stereofidelity with alkyl, aryl and 
heteroaryl Grignard reagents. The chiral auxillary is readily 
removed from the resultant sulfoximines via an unusual oxidative 
debenzylation protocol that utilises molecular oxygen as the 
terminal oxidant. This provides a general strategy for the 
synthesis of highly enantioenriched N-H sulfoximines. 
In the last few years, chiral sulfur-(VI) derivatives have received 
a considerable influx of attention in the medicinal and synthetic 
chemistry communities.[1–4] This renaissance has largely been 
driven by observations that the once neglected sulfoximine func-
tionality can imbue favourable properties to a candidate drug 
substance. Examples include the ATR inhibitor AZD 6738,[5,6] the 
anti-asthmatic Sudexanox,[7] the cyclin-dependent kinase inhibi-
tor BAY 1000394[8] and the COX inhibitor 3.[9] When compared 
to their more commonly employed achiral analogues (e.g. sul-
fones and sulfonamides), sulfoximines can offer improved solu-
bility and polarity, whilst providing an additional chiral point of 
diversity. Unsurprisingly, the stereochemistry at the sulfur atom 
has been shown to be an important factor in the bioactivity of 
many chiral sulfoximine compounds.[10] For example, considera-
ble differences are observed between the sulfur epimers of each 
of the aforementioned medicinally relevant sulfoximines (Figure 
1).  
Whilst metal- and organo-catalysed methods for the kinetic res-
olution of racemic sulfoximines have recently been devel-
oped,[11–13] there is still a scarcity of synthetic methods that pro-
vide direct access to enantioenriched sulfoximines. This is due, 
in part, to the fact that the majority of methods for sulfoximine 
synthesis[14–16] stem from the oxidation or imination of lower oxi-
Figure 1. From top to bottom: Our previous study on the racemic syn-
thesis of sulfoximines via C-S bond formation; seminal work by Reggelin 




dation state sulfur derivatives[17–27] and only a few of these meth-
ods are enantioselective. Consequently, many methodologies 
require enantiopure sulfur(IV) derivatives as substrates, such as 
sulfoxides. These are most commonly obtained in their non-ra-
cemic form using a chiral templating  strategy[28] such as the clas-
sical procedure developed by Anderson that utilises menthol de-
rived sulfinic esters.[29,30]  
For the above reasons, alternative methods for sulfoximine syn-
thesis are in high demand. In recent years, methodologies cen-
tred on C-S bond forming reactions have been gaining traction 
as an alternative strategy. For example, an unusual asymmetric 
approach to sulfoximine synthesis was reported this year that 
proceeds via the nucleophilic, S-functionalisation of sterically en-
cumbered sulfinamides.[31] A complimentary strategy utilises the 
electrophilic nature of certain sulfur(VI) derivatives. In 2018, as 
part of our own studies into the synthesis of sulfur(VI) com-
pounds,[32–39] we reported an approach to sulfoximine synthesis 
that capitalises on the reaction of sulfonimidates with organo-
magnesium reagents (Scheme 1).[39] In the same year, Sharp-
less and co-workers reported that sulfonimidoyl fluorides can 
also serve as useful synthetic intermediates in this context.[40] 
Whilst these are each effective methods, they are limited to the 
generation of racemic sulfoximines. To address this challenge, 
we sought to develop a procedure where the same mode of re-
activity could be utilised in a chiral templating strategy - compa-
rable to that used for sulfoxide synthesis. To this end, we were 
inspired by pioneering reports from Reggelin and co-workers 
concerning the cyclic sulfonimidate 1, which upon reaction with 
a small range of organometallic reagents, was shown to yield 
non-racemic sulfoximines bearing an N-valinyl moiety (Figure 
1).[41] The main limitation to this approach is that removal of the 
N-valinyl moiety requires an inconvenient 3-step deprotection 
sequence.[42] Namely, O-mesylation, bromination and finally C-N 
bond cleavage with zinc and molecular iodine. Furthermore, this 
deprotection sequence was only demonstrated on a single ex-
ample. Consequently, the method has not seen wide-spread 
adoption as a general method for the synthesis of sulfoximines. 
We reasoned however, that if this limitation could be overcome, 
a general method could be developed for the synthesis of enan-
tioenriched N-H sulfoximines. Since a number of methods exist 
for the functionalisation of these derivatives via alkylation, aryla-
tion, acylation and sulfonylation,[43–54] N-H sulfoximines are a ver-
satile and sought-after synthetic intermediate for the synthesis of 
numerous sulfoximine derivatives. 
We report here the synthesis of new chiral cyclic sulfonimidate 
scaffolds that are readily prepared from (R)-phenyl glycinol. 
These species serve as excellent chiral templates for the syn-
thesis of enantioenriched sulfoximines via their reaction with or-
ganomagnesium reagents. A salient feature of this approach is 
that the chiral auxiliary can be readily removed from the resultant 
sulfoximines in a single step via an unusual oxidative debenzyla-
tion strategy that preserves the chirality on the sulfur atom. This 
approach provides access to N-H sulfoximines in excellent yield 
and enantiomeric excess.    
Our synthetic route to the cyclic sulfonimidates 7a-9a and 7b-9b 
centres on the intramolecular oxidative alkoxylation of the corre-
sponding sulfinamides 4a-6a and 4b-6b, which are themselves 
readily available from the coupling of sulfinyl chlorides and phe-
nyl glycinol (see supporting information). In our racemic study,[39] 
the hypervalent iodine derived oxidant PhIO was employed for 
sulfonimidate synthesis.[55–57] Whilst this is an efficient proce-
dure, it has previously been reported that the sulfur stereochem-
istry is scrambled under these conditions.[55] This was corrobo-
rated in our own studies; when the sulfinamide 4a was employed 
as a single diastereoisomer, oxidation with PhIO yielded the cy-
clic sulfonimidates 7a and 7b as a 1:1 mixture of diastereomers 
(Table 1, Entry 1).  
This obstacle was overcome by using N-chlorosuccinamide 
(NCS) or tert-butyl hypochlorite (tBuOCl) as oxidants. The sulfur 
stereochemistry was preserved when these reagents were em-
ployed and the sulfonimidate 7a was obtained as a single dia-
stereomer in each case (Table 1, Entries 2-3). For the purposes 
of this study, we targeted both sulfonimidate diastereomers. Ac-
cordingly, we adopted a procedure where the sulfinamides were 
employed as a (1:1) mixture of diastereomers (Table 1, Entries 
4-9). In the case of the phenyl, methyl and tert-butyl derivatives, 
the highest yields were obtained using tBuOCl and the sulfonim-
idate diastereomers were found to be readily separable by stand-
ard column chromatography in each case (Table 1, Entries 7-9). 
With six cyclic sulfonimidates templates in hand (7a-9a and 7b-
9b), we proceeded to investigate the proposed organomagne-
sium-mediated ring opening to enantioenriched sulfoximines. 
entry R = substrate [O] result (yield) 
1a Ph 4a PhIO 7a:7b = 1:1 
2 Ph 4a NCS 7a 
3 Ph 4a tBuOCl 7a 
4 Ph 4a+4b (1:1) NCS 7a:7b = 1:1 (86%) 
5 Me 5a+5b (1:1) NCS 8a:8b = 1:1 (79%) 
6 tBu 6a+6b (1:1) NCS 9a:9b = 1:1 (60%) 
7 Ph 4a+4b (1:1) tBuOCl 7a:7b = 1:1 (92%) 
8 Me 5a+5b (1:1) tBuOCl 8a:8b = 1:1 (94%) 
9 tBu 6a+6b (1:1) tBuOCl 9a:9b = 1:1 (80%) 
Table 1. Optimisation of conditions for the synthesis of the cyclic sul-
fonimidates 7a-9a and 7b-9b. All reactions were performed at -78 °C in 
THF unless otherwise stated. Yields are for isolated material, obtained 
following column chromatography. aThis reaction was performed at 
25 °C in acetonitrile. 
 
 
The S-tert-butyl sulfonimidates 9a and 9b were found to be un-
productive as intermediates for sulfoximine synthesis (Scheme 
1). In the case of each diastereomer, only recovered starting ma-
terial was obtained upon treatment with phenyl or methyl mag-
nesium bromide. It should be noted that this is consistent with 
our previous report that acyclic S-tert-butyl sulfonimidates are 
unreactive towards Grignard reagents.[39] In contrast, the S-me-
thyl derivatives 8a and 8b each reacted smoothly with both elec-
tron-rich and –poor aryl magnesium bromides. Each of the tar-
geted sulfoximines were obtained with this approach but we 
were disappointed to observe that the products were isolated as 
a mixture of diastereomers in each case (Scheme 1). It was pos-
tulated that the observed stereo-degradation at the sulfur centre 
could be due to a competitive base-mediated ring opening, fol-
lowed by nucleophilic addition to the resultant methylene deriva-
tive 15 (Scheme 1). The observed formation of the deuterated 
derivative 16 upon quenching of the reaction mixture with 
CD3OD is consistent with this hypothesis. Moreover, when the 
S-phenyl sulfonimidates 7a and 7b were employed - which lack 
an acidic proton alpha to the sulfur – we were delighted to ob-
serve that the products were obtained as a single diastereomer 
in each case (Scheme 2). As expected, the reaction proceeds 
with inversion of the sulfur stereochemistry, as confirmed by X-
ray crystallography (see supporting information). Initially, alkyl 
substituted Grignard reagents were investigated. Pleasingly, in 
the case of each diastereomer (7a and 7b), the reaction pro-
ceeded well with methyl, cyclopropyl and isopropyl magnesium 
bromide, yielding the targeted sulfoximines as a single diastere-
omer in each case. A limit to the steric tolerance was found when 
tert-butyl magnesium bromide was employed; in these cases, 
the reaction failed to proceed and only recovered starting mate-
rial was obtained. When allyl magnesium bromide was used, the 
sulfoximines 21a and 21b were obtained, albeit in moderate 
yields (17% and 19%, respectively). Aryl organomagnesium re-
agents were particularly well tolerated and a number of S-phenyl 
Scheme 1. Evaluation of S-Me and S-tBu cyclic sulfonimidates as pre-
cursors for sulfoximine synthesis (Top). Plausible mechanism for the 
observed stereodegradation in the synthesis of the S-Me sulfoximines 
(Bottom). 
Scheme 2. Substrate scope for the formation of the enantioenriched sul-
foximines from the sulfonimidates 7a and 7b. 
 
sulfoximines were produced containing a range of electron-do-
nating and -withdrawing substituents (10 examples). The reac-
tions proceeded well with each diastereomer (7a and 7b), yield-
ing the targeted sulfoximines 22-26a and 22-26b in 80-98% 
yield. The unusual fluorene derivatives 27a and 27b could also 
be accessed with this method. Next, heteroaryl organometallics 
were trailed. Pleasingly, thienyl (28a and 28b), 3-pyridyl (29a 
and 29b) and 2-pyridyl (30a and 30b) sulfoximines could each 
be obtained with this approach. Again, forming as a single dia-
stereomer in each case. Interestingly, when ethynyl magnesium 
bromide was employed, the targeted sulfoximines 31a and 31b 
were not observed. Instead, the aziridine 32 was obtained, pre-
sumably via bromide-mediated ring-opening followed by intra-
molecular displacement. 
Finally, we investigated conditions for removal of the chiral aux-
iliary to yield enantioenriched N-H sulfoximines (Scheme 3). In 
Reggelin’s report, the analogous N-deprotection required a ra-
ther low yielding three-step procedure (Figure 1).[42] Improving 
upon this would be essential for the development of a general 
and synthetically tractable procedure. We were somewhat sur-
prised to observe that the N-benzylic functionality appeared to 
be completely robust under a range of hydrogenative debenzyla-
tion conditions (see supporting information). To combat this is-
sue, we were drawn to a report from Escolano and co-workers, 
where a rather unusual oxidative debenzylation procedure was 
utilised for the removal of the same functionality from lactam de-
rivatives.[58] This method employs molecular oxygen as oxidant 
under basic conditions in an ethereal solvent (MTBE). We were 
delighted to observe that under these conditions, the N-H sul-
foximines were obtained in good to excellent yields (Scheme 3). 
Of the 26 sulfoximines that were trialled, the only examples 
where the deprotection reaction failed to occur were the S-allyl 
sulfoximines 21a and 21b, (which yielded a complex mixture of 
degradation products) and the 2-pyridyl derivatives 30a and 30b 
(from which only recovered starting material could be obtained). 
In all other cases, the targeted N-H sulfoximines were obtained 
in good to excellent yield with this method. Crucially, the sulfur 
chirality is retained under these conditions and in each case, the 
products were obtained in excellent enantiomeric excess (93-
99% ee).  
This work constitutes a general and versatile method for the syn-
thesis of enantioenriched N-H sulfoximines via C-S bond for-
mation, allowing a modular approach to chiral sulfoximine syn-
thesis. The strategy utilises cyclic sulfonimidates as chiral tem-
plates, which are readily prepared in two steps from the simple 
and cheap amino acid derivative (R)-phenyl glycinol. The 
method provides access to either enantiomer of the desired sul-
foximines in excellent yields and stereoselectivities through re-
action of the appropriate template with a wide range of Grignard 
reagents. Removal of the auxiliary was shown to be facile in a 
single step using cheap and environmentally benign reagents.  
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